Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-04-22
DOI
https://doi.org/10.3389/fonc.2026.1847088
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib

Furong Sun, Jin Zhou, Shouzhen Liu, Yuzhu Gao et al.
Frontiers in Oncology
Cancer Immunotherapy and Biomarkers
article

Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib

Furong Sun, Jin Zhou, Shouzhen Liu, Yuzhu Gao, Jie Hua, Dong Cao, Xiaoyan Zheng
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 16
Guangzhou University of Chinese Medicine (CN), Shanghai Jiao Tong University (CN), Ruijin Hospital (CN)
Good health and well-being
Openalex Percentile: Top 22%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.